Repligen | RGEN - Sales Revenues


Repligen reported $194M in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
Agilent USD 1.84B 37M Mar/2026
Align Technology USD 1.04B 10M Mar/2026
Bio Techne USD 311.4M 15.5M Mar/2026
BioMarin Pharmaceutical USD 766M 109M Mar/2026
Bristol-Myers Squibb USD 11.49B 1.01B Mar/2026
Bruker USD 823.4M 153.8M Mar/2026
Charles River Laboratories USD 995.8M 1.6M Mar/2026
Danaher USD 5.95B 890M Mar/2026
Dentsply International USD 880M 81M Mar/2026
General Electric Aerospace USD 11.6B 270M Mar/2026
Henry Schein USD 3.37B 30M Mar/2026
Illumina USD 1.09B 70M Mar/2026
IQVIA Holdings USD 4.15B 210M Mar/2026
Mettler Toledo International USD 947.13M 182.87M Mar/2026
Myriad Genetics USD 200.4M 9.4M Mar/2026
OraSure Technologies USD 26.76M 322K Dec/2025
Pacific Biosciences Of California USD 44.64M 6.2M Dec/2025
Pfizer USD 14.5B 3.08B Mar/2026
Repligen USD 194M 3.91M Mar/2026
Revvity USD 711M 61.06M Mar/2026
Standard Biotools USD 21.1M 2.7M Mar/2026
Thermo Fisher Scientific USD 11.01B 1.2B Mar/2026
Waters USD 1.27B 338M Mar/2026
West Pharmaceutical Services USD 844.9M 39.9M Mar/2026